Daniel A. Ollendorf

Daniel A. Ollendorf publication distribution in Economics and Finance in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Economics and Finance in 2026. The highlighted bar marks where Daniel A. Ollendorf sits on this spectrum.

Daniel A. Ollendorf D-index placement in Economics and Finance in 2026

The chart shows the D-index (discipline H-index) distribution of Economics and Finance scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel A. Ollendorf sits on this spectrum.

Best Publications

• Medication Compliance and Persistence: Terminology and Definitions

  Joyce A. Cramer;Anuja Roy;Anita Burrell;Carol J. Fairchild

  2885
  Citations

• Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

  Dhruv S. Kazi;Andrew E. Moran;Pamela G. Coxson;Joanne Penko

  415
  Citations

• Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer: A Decision Analysis

  Julia H. Hayes;Daniel A. Ollendorf;Steven D. Pearson;Michael J. Barry

  274
  Citations

• Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018.

  David D. Kim;David D. Kim;Madison C. Silver;Natalia Kunst;Natalia Kunst;Joshua T. Cohen;Joshua T. Cohen

  243
  Citations

• Potential Economic Benefits of Lower-Extremity Amputation Prevention Strategies in Diabetes

  Daniel A Ollendorf;James G Kotsanos;William J Wishner;Mark Friedman

  199
  Citations

• Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients

  Daniel A. Ollendorf;Montserrat Vera-Llonch;Gerry Oster

  175
  Citations

• Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.

  Dhruv S. Kazi;Joanne Penko;Pamela G. Coxson;Andrew E. Moran

  169
  Citations

• Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population

  Harinder S. Chahal;Elliot A. Marseille;Jeffrey A. Tice;Steve D. Pearson

  163
  Citations

• Observation Versus Initial Treatment for Men With Localized, Low-Risk Prostate Cancer: A Cost-Effectiveness Analysis

  Julia H. Hayes;Daniel A. Ollendorf;Steven D. Pearson;Michael J. Barry

  148
  Citations

• Identifying the Need for Good Practices in Health Technology Assessment : Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA

  Finn Børlum Kristensen;Don Husereau;Don Husereau;Mirjana Huić;Michael Drummond

  127
  Citations

• End-stage renal disease-associated managed care costs among patients with and without diabetes.

  Amie T. Joyce;John M. Iacoviello;Soma Nag;Shiva Sajjan

  109
  Citations

• Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.

  Sumeyye Samur;Matthew Klebanoff;Reiner Banken;Daniel S. Pratt

  103
  Citations

• Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population

  Daniel A. Ollendorf;David Klingman;Elisabeth Hazard;Saurabh Ray

  101
  Citations

• Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers

  Daniel A. Ollendorf;Richard H. Chapman;Steven D. Pearson

  98
  Citations

• Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis

  Melanie D. Whittington;R. Brett McQueen;Daniel A. Ollendorf;Jeffrey A. Tice

  95
  Citations

• Cost-Effectiveness of Sacubitril–Valsartan in Patients With Heart Failure With Reduced Ejection Fraction

  Alexander T Sandhu;Daniel A Ollendorf;Richard H Chapman;Steven D Pearson

  89
  Citations

• An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia

  Libby Black;Michael James Naslund;Thomas D. Gilbert;E. Anne Davis

  83
  Citations

• Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma

  Melanie D. Whittington;R. Brett McQueen;Daniel A. Ollendorf;Varun M. Kumar

  81
  Citations

• Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.

  Melanie D Whittington;R Brett McQueen;Daniel A Ollendorf;Varun M Kumar

  77
  Citations

• Economic Consequences of Venous Thromboembolism Following Major Orthopedic Surgery

  Gerry Oster;Daniel A Ollendorf;Montserrat Vera-Llonch;May Hagiwara

  70
  Citations